

1 **Extracellular vesicles in the pathogenesis of *Campylobacter jejuni***

2

3 Jeanne Malet-Villemagne^{a,*}, Jasmina Vidic^{a,*}

4

5 ^a Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Domaine de Vilvert, 78350

6 Jouy en Josas, France

7

8 *Corresponding authors: jeanne.villemagne@gmail.com; jasmina.vidic@inrae.fr

9

10 **Abstract**

11 Bacteria in genus *Campylobacter* are the leading cause of foodborne infections worldwide.

12 Here we describe the roles of extracellular vesicles in the pathogenesis of these bacteria and

13 current knowledge of vesicle biogenesis. We also discuss the advantages of this alternative

14 secretion pathway for bacterial virulence.

15

16 **Keywords**

17 Extracellular vesicles; Secretion system; Virulence factors; Gram-negative bacteria;

18 *Campylobacter*.

19

20 1. Introduction

21 *Campylobacter* is a genus of spirally curved, Gram-negative, non-fermentative,
22 microaerophilic, and non-spore-forming zoonotic bacteria. The majority of *Campylobacter*
23 species are characterized by their rapid, corkscrew-like motility, which is mediated by an
24 unsheathed, polar flagellum at one or both ends. Since the first isolation of *Campylobacter*
25 from the colon of dead children in 1886 by Theodore Escherich, the taxonomy of this genus
26 has received extensive scrutiny and undergone numerous modifications. According to the
27 most-recent taxonomic structure, there are currently 50 species of *Campylobacter* and 16
28 subspecies yet to be described [1], although the classification scheme of the WHO recognizes
29 only 17 species and 6 subspecies [2]. Of these, the four thermophilic species *Campylobacter*
30 *jejuni*, *Campylobacter coli*, *Campylobacter lari*, and *Campylobacter upsaliensis* are those most
31 commonly associated with human infection.

32 *Campylobacters* are the most common cause of foodborne bacterial gastroenteritis
33 worldwide, with 1.5 million cases estimated annually in the United States [3] and 120,946
34 cases reported in Europe in 2020 [4]. The overall economic burden of campylobacteriosis was
35 estimated at about €3 billion in the EU [5], and US\$ 4 billion in the US annually [6]. More than
36 90% of human campylobacteriosis cases are caused by *C. jejuni* and *C. coli*, with the vast
37 majority (over 80%) due to *C. jejuni* [7]. Unlike *Salmonella* or *Listeria*, *Campylobacter* spp. are
38 not able to multiply within foods and are not associated with large outbreaks. More than 90%
39 of cases of human campylobacteriosis are sporadic.

40 Identification of campylobacters is challenging using traditional microbiological
41 culturing techniques. These bacteria are considered to be fastidious microorganisms because
42 they can neither ferment nor oxidize carbohydrates. Their optimum growth temperature is
43 between 37–42°C, but their culturing requires special medium and conditions such as the

44 addition of blood to a culture broth and mandatory microaerobic environments [8]. The
45 biochemical/phenotypical characterization of campylobacters is also difficult because they
46 can change their distinctive “S”-shape into a coccoid form. Given these challenges, the
47 increased incidence of illnesses associated with these bacteria, and the inadequacies of
48 current therapies, there is an urgent need for the development of new strategies for control
49 and treatment. Such strategies will draw inspiration from studies of *Campylobacter*'s ability
50 to invade, replicate within the host, and survive in the face of stressors, research that is rapidly
51 improving our understanding of its dissemination, ability to escape from host immune
52 defenses, and adaptation to different environments.

53 In this review, we first introduce the main virulence factors involved in various steps of
54 infection by *Campylobacter*, and then present a synthesis of current knowledge concerning
55 the role of bacterial extracellular vesicles (BEVs) in its pathogenesis. We discuss the
56 importance of BEVs in this bacterium's lifestyle, dissemination, and infection process,
57 particularly given the absence of other genes for prototypical secretion systems in the genome
58 of *Campylobacter*.

59

60 **2. Campylobacteriosis and virulence of campylobacters**


61 Campylobacters, like other bacteria, have developed complex systems for exporting effectors
62 and virulence factors in order to adapt to adverse conditions or colonize new habitats. When
63 exposed to an unfavorable environment, campylobacters produce virulence factors that can
64 also act as antimicrobial resistance factors or niche factors at various steps along the food
65 chain or during infection. In addition, in the presence of oxygen or under antibiotic pressure,
66 *C. jejuni* may enter a “persister state” [9], a non-growing state in which
67 reduction/dysregulation in metabolic processes enables bacterial cells to survive lethal stress

68 conditions. The metabolic burst in the persister phenotypic variant has been proposed to
69 result from a reduction in membrane potential due to remodeling of the electron transport
70 chain [9], which prevents hyperpolarization of the inner membrane and curbs intracellular
71 alkalization. In the persister state, cells of *C. jejuni* demonstrate reduced respiration and
72 nutrient transport and considerable modulation of gene expression; however, when
73 environmental conditions become favorable again, these bacteria may return to their original
74 phenotype and cause infection [9].

75 This zoonosis is transmitted through consumption of under-cooked poultry meat and
76 meat products (up to 80% of cases), as well as raw milk, shellfish, vegetables, and contact with
77 animals [10]. The majority of cases of campylobacteriosis are reported during the summer
78 season, likely associated with outdoor barbecues [4]. However, campylobacters can also
79 survive in water, and infection may occur following contact with contaminated water during
80 recreational activities. Clinical symptoms of illness range from self-limiting diarrhea to severe
81 inflammatory and bloody diarrhea, sometimes associated with systemic issues. Most of the
82 time, symptoms follow an incubation period of 2 to 5 days and are limited to gastroenteritis
83 with diarrhea, fever, abdominal cramps, and vomiting lasting from 2 to 10 days [7]. The
84 infective dose in a human host is low, around 500–800 bacteria [11]. Even if the majority of *C.*
85 *jejuni* infections remain uncomplicated, this pathogen is the main infectious agent identified
86 in peripheral neuropathies such as Guillain-Barré syndrome [12] or Miller-Fisher syndrome,
87 which can lead to death in 2–12% of patients, depending on their age. Finally,
88 campylobacteriosis may result, in rare cases, in intestinal complications (colitis, appendicitis,
89 irritable bowel syndrome, colorectal cancer, Barrett's esophagus) or systemic infections
90 (endocarditis, pneumonia, neonatal sepsis). The true incidence of campylobacteriosis is

91 estimated to be under-reported by a factor of 10, mainly due to misdiagnosis or improper
 92 sample collection and testing [13].

93 The clinical presentation of *Campylobacter* infections is influenced by a range of virulence
 94 factors used by the bacterium to target host cells, adhere to mucus, invade epithelial cells,
 95 and cause cell damage. To date, the pathogenesis of *C. jejuni* remains poorly understood due
 96 to the complexity of the genetic mechanisms involved and a lack of appropriate animal models
 97 for research. However, multiple virulence factors expressed by this bacterium are implicated
 98 in crucial steps of pathogenesis, as illustrated in Fig. 1.



99
 100 **Figure 1. The process of infection by the intestinal pathogen *Campylobacter jejuni* and the**
 101 **virulence factors implicated.** The infectious process of *C. jejuni* begins when the bacteria
 102 reach the intestinal epithelial cells of the host and then adhere to and invade those cells. Two
 103 models are presented for *C. jejuni*'s migration through the epithelium (violet / sky blue). Once
 104 internalized, *C. jejuni* produces CDT toxins (cytolethal distending toxins), which provoke DNA
 105 double-breaks thanks to their DNase-like activity, leading to cell death and inflammation.
 106 Then, the bacteria may survive or be cleared from the host. Virulence factors are noted in
 107 green.

108

109 **2.1. Reaching target host cells**

110 For enteric pathogens, a key step of infection is colonization of the intestinal epithelial cells.
111 This process requires the ability to penetrate the mucus layer covering epithelial cells in order
112 to reach the target cells and then internalize. *Campylobacter* species are naturally able to
113 swim very rapidly in viscous environments due to their helical shape and amphitrichous
114 flagella. Indeed, *C. jejuni* has been documented to travel at a higher velocity in mucus than
115 most other bacteria (55 to 100 $\mu\text{m}\cdot\text{s}^{-1}$; [14]).

116 Given the crucial role of the flagellum in the colonization process, the flagellar proteins are
117 considered to act as bacterial virulence factors. In addition to motility, the flagellum is involved
118 in biofilm formation, adhesion, internalization, and protein secretion [15], [16]. The basic
119 structure of a bacterial flagellum consists of an extracellular filament connected via a hook to
120 a basal body formed of rings and a rod. The basal body complex comprises the MS ring (FlhF
121 protein), the C ring rotor (FlhG, FlhM, FlhN, FlhY), the P-ring in the peptidoglycan layer and the L-
122 ring in the outer membrane (FlgI and FlgH, respectively, described in other Gram-negative
123 bacteria), the rod (FlgF and FlgG), and a motor (MotA, MotB) responsible for the rotation
124 force. This assemblage anchors the flagellum to the bacterial envelope with the help of a hook
125 (FlgE) and surrounds the type III secretion system (T3SS) localized in the inner membrane. The
126 flagellar T3SS is composed of the proteins FlhA, FlhB, FlhO, FlhP, FlhQ, and FlhR, and exports distal
127 flagellar fragments through the membranes to construct the extracellular filament, formed by
128 the two glycosylated flagellins FlaA and FlaB [17]. The monomers at the distal end of the
129 filament are covered with the flagellar capping protein FlhD [18].

130 A bacterium's route and directional changes during swimming are determined by the
131 rotational direction of the flagellum, which alternates between clockwise and counter-
132 clockwise depending on extracellular signals. The rotational direction of the flagellum is


133 usually coupled to chemosensory receptors, enabling the bacterium to reach a favorable
134 environment [19]. Bacterial movement driven by gradients of oxygen, nutrients, or
135 temperature—called chemotaxis—may play an important role in both the commensal and
136 pathogenic lifestyles of *Campylobacter*. Various extracellular signals are detected by methyl-
137 accepting chemotaxis proteins (MCPs), also called transducer-like proteins (Tlps). Once the
138 external stimuli bind to Tlps, a signal is relayed to chemotaxis proteins (Che) in the cytoplasm.
139 These proteins initiate a signal transduction cascade resulting in directional rotation of the
140 flagellum. To date, 13 Tlps and 6 Che proteins have been described in *C. jejuni* [20]. Notably,
141 the loss of CheY creates bacteria that are non-motile and non-invasive. For *C. jejuni*,
142 chemotaxis is as essential as motility for reaching intestinal cells and colonizing the gut of
143 chickens and mammals [21].

144

145 **2.2. Adhesion and invasion of host cells: two models for transepithelial migration of *C.*** 146 ***jejuni***

147 After reaching the gut, *C. jejuni* must cross the mucus layer and adhere to intestinal epithelial
148 cells in order to invade them. A series of studies in human biopsies have shown that *C. jejuni*
149 is able to cross the epithelial barrier and enter underlying tissues, organs, and the bloodstream
150 [22]. However, the mechanism of this transmigration through the intestinal epithelium is still
151 debated and not well understood. To explain how *C. jejuni* is able to cross polarized epithelial
152 cells, two transmigration routes have been hypothesized: (i) the transcellular route, in which
153 bacteria cross the epithelial barrier through adhesion and cell entry at the apical pole and exit
154 at the basal pole [22], and (ii) the paracellular route, in which pathogens open cell junctions
155 using proteases like HtrA [23] and make their way between cells by adhering to basal
156 extracellular matrix components like fibronectin before finally invading a cell at the basal pole

157 (Fig. 2). The adhesion and invasion steps of pathogenesis may therefore occur either at the
 158 apical pole or at the basal one, depending on the route taken by *C. jejuni*.



159

160 **Figure 2. The two models hypothesized for the epithelial transmigration of *Campylobacter***
 161 ***jejuni* during infection.** In the transcellular route, bacteria adhere to and invade the apical
 162 pole of epithelial cells and exit by the basal pole. In the paracellular route, bacteria cleave cell
 163 junctions to cross the epithelial barrier between two cells, and once at the basal pole, adhere
 164 to and invade the cell.

165

166

167 **2.2.1. Adhesion**

168 As for many bacteria, adhesion of *C. jejuni* is a multifactorial process. Several binding factors
169 have been implicated in the successful interaction with host cells and the development of
170 disease. Depending on the transmigration route taken by the bacterium, adhesion may occur
171 either at the apical pole (adhesion to mucus or directly to epithelial cells) or at the basal one
172 (adhesion to extracellular matrix components like fibronectin).

173 Certain adhesion factors found in *C. jejuni* have been shown to promote basal adhesion to
174 fibronectin, a large and ubiquitous glycoprotein that is the main component of the
175 extracellular matrix of mammalian cells. Binding to this protein is the primary step of
176 attachment to tissue surfaces for numerous pathogens. Of the adhesins that have been found
177 to bind to fibronectin, three are of particular interest: the major outer membrane protein,
178 MOMP [24], and the outer membrane proteins CadF (*Campylobacter* spp. adhesion to
179 fibronectin) and FlpA (fibronectin-like protein A). Studies of *cadF* and *flpA* mutants have
180 revealed impairments in binding to epithelial cells, colonization of the chicken gut, and the
181 establishment of severe disease in germ-free mice [25], [26]. These proteins promote
182 adhesion via their fibronectin-binding sites, which consist of a four-amino-acid motif (Phe-Arg-
183 Leu-Ser) for CadF and a nine-amino-acid motif (Trp-Arg-Pro-His-Pro-Asp-Phe-Arg-Val) for FlpA
184 [27].

185 Other proteins enhance the adhesive properties of bacteria via their chaperone
186 activity, assisting in the folding of outer membrane proteins and thus in modifications to the
187 bacterial surface. The best example is the serine protease HtrA, a highly conserved periplasmic
188 protein displaying both protease and chaperone activity. A loss of HtrA chaperone activity
189 leads to a strong reduction in bacterial binding to epithelial cells, more so than the loss of any
190 other known adhesin [28].

191 Some proteins have been identified as adhesins but the mechanism by which they bind
192 epithelial cells is still unknown. An example of this is Peb1, the first protein identified in *C.*
193 *jejuni* as being involved in bacterial adhesion to HeLa cells and the colonization of mice [29].
194 Another example is CapA, an autotransporter protein of the outer membrane protein; CapA
195 is not conserved among all strains of *C. jejuni*, but when it is present this surface-exposed
196 protein plays a role in binding to epithelial cells and is required for efficient colonization of
197 chickens [30]. Important roles in adhesion have also been identified for some flagellar and
198 motility proteins, which are required for adhesion and invasion of the intestinal tract. For
199 example, FlaC binds to HEP-2 cells, such as the surface-exposed lipoprotein JlpA (*jejuni*
200 lipoprotein A), but the mechanism for this is unknown [31].

201 The adhesion process also appears to depend on certain non-protein components, such
202 as polysaccharides or plasmids. Many strains of *C. jejuni* are thought to produce both
203 lipooligosaccharides (LOS) and high-molecular-weight lipopolysaccharides (HMW LPS), which
204 are considered more as highly variable capsular polysaccharides than as LPSs. It is through
205 these polysaccharides that the *C. jejuni* capsule participates in the processes of adherence and
206 invasion. For example, strains with mutations in three LOS synthesis genes (*wlaRG*, *wlaTB*, and
207 *wlaTC*) all displayed reduced adhesion to chicken embryo fibroblasts [32]. Interestingly, the
208 similarity between the LOS of *C. jejuni* and neuronal gangliosides is thought to explain the link
209 between *C. jejuni* and Guillain-Barré Syndrome. Another intriguing example of a non-protein
210 component with a role in adhesion is provided by the *C. jejuni* resistance plasmid pVir, which
211 carries the gene *comB3*; mutation in this gene was found to result in decreased adhesion and
212 invasion of INT-407 cells [33].

213 **2.2.2. Cell invasion**

214 In 2001, Rivera-Amill *et al.* demonstrated that certain proteins—designated Cia for
215 *Campylobacter* spp. invasion antigens—are secreted during co-cultivation of *C. jejuni* and
216 intestinal cells [34]. More precisely, they identified a temporal association between the
217 secretion of Cia proteins and the invasion of cells by *C. jejuni*: Cia proteins are secreted after
218 30 minutes of co-culturing, at the precise moment when a rapid increase in the internalization
219 of bacteria is observed. Because the genome of *C. jejuni* lacks genes associated with a classical
220 type III secretion system, the flagellar export apparatus was identified as the likely mechanism
221 of Cia secretion [34]. Further investigations into CiaB suggested that this protein may be
222 essential for cell invasion, as three mutants with insertional disruptions of the *ciaB* gene
223 exhibited a significant reduction in internalization in host cells [35]. Interestingly, Cia protein
224 synthesis was found to be enhanced in the presence of deoxycholate bile acid, but Cia
225 secretion was unchanged. This finding suggests that production of Cia proteins may occur
226 early in the colonization process, but secretion is only initiated once the bacterium has
227 adhered to its long-term colonization site [34].

228 In addition to their roles in adhesion, some flagellins and flagellar components also
229 contribute to epithelial cell invasion by *C. jejuni*. In studies of mutant strains, Grant *et al.*
230 demonstrated that flagella are important for *C. jejuni*'s internalization in epithelial cells [16].
231 Notably, the protein FlaC, which, like Cia proteins, is secreted by the flagellar apparatus, has
232 been shown to be required for invasion [31]. Similarly, the Δ *motAB* mutant strain, lacking the
233 genes encoding the flagellar motor, demonstrated a significant decrease in cell invasion
234 capacity [36].

235 Finally, some lysophospholipids contained in the membrane of *C. jejuni* are also
236 considered to be novel virulence factors. Short lysophosphatidylethanolamines (lysoPE) were
237 reported to permeabilize cell membranes and thus cause cell damage via oxidative stress [37].

238

239 **2.3. Toxin production and pro-inflammatory factors**

240 After *C. jejuni* interacts with epithelial cells, it releases a holotoxin—cytolethal distending toxin
241 (CDT)—that may be responsible for the cytopathic effects of *C. jejuni* infection. CDT belongs
242 to a family of bacterial toxins that affect the epithelial cell layer and interrupt the cell division
243 process, leading to cell death [38]. This toxin is produced by a wide range of pathogenic Gram-
244 negative bacteria including *Escherichia coli*, *Helicobacter* spp., and other species of
245 *Campylobacter*. The CDT of *C. jejuni* belongs to the AB family of toxins, which feature an active
246 subunit (CdtB) and two binding subunits (CdtA and CdtC) encoded by the *cdtA*, *cdtB*, and *cdtC*
247 genes located in the same operon [39].

248 The subunits CdtA and CdtC are thought to enable the binding of CDT to epithelial cells by
249 attaching themselves to the cholesterol-rich lipid rafts of the cell membrane, thus facilitating
250 the entry of CdtB into the cell cytoplasm. CdtB is now known to be the toxic component, as a
251 microinjection or transfection of only this subunit into host cells causes the same cell cycle
252 arrest observed with the complete CDT toxin. Once in the cell, CdtB reaches the cell nucleus
253 and causes DNA damage (double-strand breaks). CdtB is thought to act as a deoxyribonuclease
254 I, as it shares structural similarity with DNase I-like proteins [40]. Host cells react to this DNA
255 damage by initiating a regulatory cascade that includes phosphorylation of the histone protein
256 H2AX, leading to the recruitment of Rad50, a DNA-repair protein for double-strand breaks
257 [41]. This process blocks the cell cycle at the G2/M interphase to allow for DNA repair. If the
258 damage is too extensive, repair fails and the cell cycle arrest leads to cellular distention,
259 senescence, and finally cell death [42].

260 The CDT toxin has been reported to provoke autophagy and apoptosis in vitro and
261 inflammation in vivo, along with cell senescence. A recent study in colonic epithelial cells

262 highlighted CDT-induced pyroptosis, a newly discovered process of pro-inflammatory
263 programmed cell death characterized by the emergence of large bubbles from the plasma
264 membrane, which leads to cell membrane rupture and eventually the release of cell content.
265 This form of programmed cell death was originally known to be triggered by pro-inflammatory
266 caspases but it now appears that it can also be mediated by virulence factors [43]. Specifically,
267 Gu *et al.* demonstrated the induction of gasdermin E-mediated pyroptosis in response to the
268 CDT of *C. jejuni*. After CDT exposure, there was a considerable elevation in ROS levels in
269 epithelial cells, initiating the caspase-9/caspase-3/gasdermin E pyroptosis pathway [43]. This
270 toxin-induced inflammation may be further exacerbated by the pro-inflammatory effects of
271 many other virulence factors expressed by *C. jejuni* (e.g., Omp18, CjaA, CjaC), leading to tissue
272 damage and the clinical signs of campylobacteriosis.

273 **2.4. Survival**

274 During commensal carriage in food animals, *C. jejuni* must cope with various stresses related
275 to oxygen levels, desiccation, disinfectants, or temperature shocks. In these environments, *C.*
276 *jejuni* may also encounter bile salts, antibiotics, and defenses of the host immune system.
277 Resistance to many drugs and bile salts is often mediated by the *Campylobacter* multidrug
278 efflux pump (CME), encoded by the *cmeABC* operon [44]. To protect itself from disinfection
279 protocols, desiccation, and high oxygen levels, *C. jejuni* is able to form biofilms [45]. In
280 addition, this bacterium is able to enter a viable-but-not-culturable (VBNC) state in response
281 to osmotic and temperature shocks, pH modification, or nutrient starvation [45]. A final form
282 of defense is the S-layer and capsular polysaccharides (CPS) that coat *C. jejuni* cells, which are
283 involved in cell wall maintenance but have also been implicated in evasion from the host
284 immune system [46].

285

286 3. Extracellular vesicles in Gram-negative bacteria and *C. jejuni*

287 3.1. Secretion of extracellular vesicles in Gram-negative bacteria


288 Bacteria constitutively release extracellular vesicles, termed bacterial extracellular vesicles
289 (BEVs), which vary in their composition, size, content, and architecture depending on the
290 biogenesis route, growth phase, and environmental conditions present (e.g., pH, temperature,
291 nutrient content, ionic force, antibiotic pressure, or oxygen stress). The liberation of
292 membrane vesicles from Gram-negative bacteria is thought to be an alternative secretion
293 system that facilitates both interbacterial and bacterial-host cargo transfer. Indeed, vesicles
294 from Gram-negative bacteria were shown to integrate into the membranes of foreign
295 bacteria, both Gram-positive and Gram-negative [47]. Vesicles may also adhere to or integrate
296 into eukaryotic cells, promoting adherence of the parent bacterium to host cells. There is an
297 increasing body of evidence that BEVs are the cause of numerous pathologies, through either
298 bacterial-bacterial or bacterial-host interactions [48], [49]. Nanosized BEVs are released in
299 both favorable and unfavorable physiological conditions as a mechanism for cell-free
300 intracellular communication.

301 Through their roles in bacterial short- and long-distance communication, stress
302 response, detoxification, lateral gene transfer, and intracellular competition, BEVs allow
303 bacteria to interact rapidly and adapt to their environments, and thus to cause various
304 pathologies [50]. In particular, BEVs have a direct impact on pathogenesis by delivering toxins
305 and other virulence factors to the host during infection [51]. Indeed, in *C. jejuni*, the well-
306 characterized toxin CDT is secreted in its active form via BEVs [52]. Bacterial vesicles may
307 internalize into epithelial or immune cells or fuse with eukaryotic membranes to release their
308 cargo inside the cytoplasm. In addition to toxin delivery, BEVs enable long-distance delivery
309 of virulence factors such as adhesins, colonization factors, outer membrane proteins, LPSs,

310 flagellins, and proteases [53]. BEVs are particularly suitable for delivering insoluble proteins
311 and proteins lacking signal peptides. Additionally, by densely packaging virulence factors, BEVs
312 increase their stability and concentration until delivery to the target. They also provide a
313 protective barrier, safeguarding their contents against degradation by host proteases or
314 nucleases, or low/high concentrations of salt or cations. Compared to classical secretion
315 systems that export individual virulence factors, BEVs may enhance pathogenesis through the
316 coordinated delivery of multiple, densely packed factors.

317 BEVs can be easily observed in bacterial preparations by electron microscopy. They
318 may be formed from cellular debris during cell lysis (Fig. 3a), but can also be generated through
319 bacterial metabolic activities. The generation of extracellular vesicles under non-lytic
320 conditions is beneficial for bacteria by eliminating misfolded proteins and relieving membrane
321 stress. In this process, the outer membrane swells to form outer membrane vesicles (OMVs)
322 that are then released in the medium (Fig. 3b). The resulting liberated spherical particles,
323 ranging in diameter from 10 to 500 nm, consist mainly of periplasmic proteins and envelope
324 components such as phospholipids, lipoproteins, LPSs, lipooligosaccharides (LOS), and outer
325 membrane proteins (Fig. 3e). Moreover, Gram-negative bacteria may produce double-
326 membrane bilayer vesicles via the protrusion of both the outer and cytoplasmic membrane
327 (Fig. 3c). These so-called outer-inner membrane vesicles (O-IMVs) are believed to carry
328 bacterial cytoplasmic content, e.g., proteins, ATP, nucleic acids, effectors, and quorum-
329 sensing molecules (Fig. 3c and f) [54]. Several Gram-negative bacteria have also been shown
330 to liberate nanosized filaments attached to OMVs [48], [55]. When a nanofilament forms as a
331 continuous tubular structure that resembles multiple OMVs, it is called a nanotube (Fig. 3d);
332 when the nanofilament is instead attached to a single OMV, it is called a nanopod. Nanotubes


333 and nanopods may bridge different cells together and facilitate their communication via
 334 OMVs.



335
 336 **Figure 3. Diverse mechanisms of bacterial extracellular vesicle (BEV) secretion and content**
 337 **of the resulting vesicles. (a)** OMVs can be formed by a bleb of the outer membrane or **(b)**
 338 during cell lysis. **(c)** BEVs may also be formed by a protrusion of both the inner and outer
 339 membranes, forming O-IMVs. **(d)** BEVs can be secreted in a nanofilament containing one
 340 vesicle (nanopods) or several (nanotubes). **(e-f)** These different mechanisms result in
 341 differences in the contents of secreted vesicles.

342
 343 *C. jejuni* cells, which are approximately 1–4 μm long, can liberate vesicles of diameters
 344 reaching 300–500 nm (Fig. 4). The biogenesis and liberation of BEVs of this size represent a
 345 huge loss of both membrane and energy. This strongly suggests that BEVs have vital roles in
 346 the maintenance of normal bacterial physiological activities. Campylobacters have been
 347 observed to produce BEVs both in the presence and absence of stress. To date, though, no
 348 model has been proposed for BEV biogenesis in *Campylobacter*, and the mechanisms
 349 described in other Gram-negative bacteria appear to be species-specific. For instance,
 350 *Pseudomonas aeruginosa*, which has a highly fluid membrane, can produce BEVs only when

351 outer membrane fluidity is reduced, which occurs in response to the interaction between the
352 quorum-sensing pseudomonas quinolone signal (PQS) molecule and lipid A protein [56]. Once
353 the outer membrane is stabilized, the membrane curvature enables formation of BEVs.
354 Another mechanism, proposed for *Salmonella*, involves modifications in the connections
355 between the cell wall and the outer membrane that allow blebbing [57]. This mechanism is
356 supported by the observation that BEVs are released with high frequency at cell division sites.
357 Nevertheless, this model cannot be considered universal because BEVs can also be released
358 from other cell sites. Finally, bacteria whose flagellum is sheathed with LPS, such as *Vibrio*
359 *fischeri* or *Vibrio cholerae*, have been shown to release BEVs via flagellar rotation [58].



360
361 **Figure 4. Scanning electron microscopy image of *Campylobacter jejuni* and its purified**
362 **extracellular vesicles. (a) *C. jejuni* on a BHI plate. Its S-shaped morphology, polar flagella, and**
363 **extracellular vesicles (yellow arrows) can be observed. (b) Extracellular vesicles secreted by *C.***
364 ***jejuni* are heterogenous in size, ranging in diameter from around 20 nm to 300 nm. Scale bars**
365 **= 500 nm.**

366

367 One model that may be more generally applicable is that proposed by Roier *et al.* based
368 on the maintenance of lipid asymmetry (MLA) pathway [59]. This pathway is highly conserved
369 in Gram-negative bacteria and is involved in the retrograde trafficking of phospholipids from

370 the outer leaflet of the outer membrane to the inner membrane. When this retrograde
371 trafficking is blocked or down-regulated, the accumulation of phospholipids in the outer
372 leaflet of the outer membrane leads to an asymmetric expansion and the formation of BEVs.
373 The role of this pathway in BEV production in *C. jejuni* was confirmed by Davies *et al.* [60].
374 Using the bile salt sodium taurocholate as a potential regulator, they observed that *C. jejuni*
375 regulated BEV production through the MLA pathway without compromising membrane
376 stability. In the presence of sodium taurocholate, BEV production was enhanced in the wild-
377 type strain but not in an *m1aA* mutant that lacked the outer membrane component of the MLA
378 pathway. This work suggests that *C. jejuni* is able to produce BEVs of different sizes, numbers,
379 and cargos depending on signals from the host gut, and moreover, that such environmental
380 signals may be responsible for triggering different mechanisms for BEV biogenesis.

381

382 **3.2. Implication of BEVs in *C. jejuni* virulence**

383 In contrast to archetypal Gram-negative bacteria, which have six secretion systems for
384 exporting molecules (Type I to Type VI, T1SS-T6SS), genetic analyses of *Campylobacter* isolates
385 suggest that this bacterium may rely only on Type III and IV, with a few genes that encode
386 proteins of the Type II and VI systems [61]. However, to date no functional T4SS has been
387 identified in *Campylobacter* spp. In *C. jejuni*, the T3SS is a needle-like macromolecular machine
388 that transports protein complexes across the inner and outer membrane in a single step
389 without a periplasmic intermediate (Sec-independent). It is unique in that, unlike in other
390 pathogenic bacteria in which there is a version of the T3SS dedicated solely to the flagellum,
391 the T3SS in *C. jejuni* appears to be dual-functional [61]: it transports not only flagellar proteins
392 such as flagellin and allied proteins, but also releases some non-flagellar virulence factors such

393 as the invasion antigen Cia proteins and FlaC, which plays a role in cell adhesion and invasion
394 [31].

395 Due to the absence of genes for prototypical secretion systems in their genome,
396 campylobacters must use alternative mechanisms to secrete virulence factors in host cells and
397 so exert their pathogenic effects. Like other Gram-negative bacteria, campylobacters seem to
398 rely on extracellular vesicles to transport virulence factors. As mucosal pathogens,
399 campylobacters use BEVs to coordinate the secretion of major virulence factors (active
400 proteins, nucleic acids, metabolites, peptidoglycan fragments) and to deliver them in the
401 cytoplasm of host cells rather than in the surrounding medium. Indeed, it has been
402 demonstrated that *C. jejuni* uses BEVs to deliver toxins [52] and certain proteins that promote
403 adhesion and invasion of host cells [62]. BEVs carrying CDT have been shown to directly
404 damage cellular DNA and induce apoptosis in a range of mammalian cell lines [63].
405 Furthermore, the addition of isolated BEVs was found to improve the adhesion and
406 internalization of *C. jejuni* to Caco-2 epithelial cells, confirming the importance of BEVs in
407 establishing infection [64].

408 A few studies have attempted to characterize the proteinaceous cargo of the BEVs
409 secreted by *C. jejuni* under different conditions. Vesicles have been reported to contain
410 numerous and diverse proteins described or predicted as virulence factors with a role in the
411 pathogenesis of *C. jejuni* (Table 1). First among these are the flagellar proteins (flagellins FlaA,
412 FlaB, FlaC, and FlaD, and flagellar hook proteins FlaE, FlgE, FlgK, FlgL, FlgP, and FliD), which
413 have been found in OMVs secreted by different strains of *C. jejuni* (81-716 and 11168) and at
414 different growing temperatures (37°C and 42°C)[65], [66], [67], [68]. As mentioned earlier,
415 these proteins, which form components of the flagellum, are considered virulence factors of
416 pathogenic bacteria because of the importance of the flagellum in motility, adhesion, and

417 stimulation of the host immune system. Many different adhesins have also been found in
418 vesicles, notably the fibronectin binding proteins FlpA and CadF, the lipoproteins RlpA and
419 JlpA, and the capsule polysaccharide export protein KpsD [62], [65], [66], [67]. In addition,
420 vesicles have been found to contain three outer membrane proteins identified as virulence
421 factors: the Omp18 protein, implicated in adhesion and immune system stimulation; the ChuA
422 heme receptor protein, involved in adhesion and invasion of host cells; and the major outer
423 membrane protein (MOMP) PorA, which plays a role in the adhesion of *C. jejuni* to intestinal
424 cells [67]. An analysis of the content of vesicles from strain 81-176 detected a chemoreceptor
425 protein, CheV [66], which is involved in chemotaxis, driving the directional changes during
426 swimming to allow bacteria to reach target cells, and is thus implicated in the first step of
427 pathogenesis. Vesicles secreted by *C. jejuni* strain 81-176 were also found to contain the
428 molecular chaperone GroEL, which has multiple roles in pathogenesis, namely adhesion,
429 invasion, and immune system stimulation. BEVs from strains 81-187 and 11168 have been
430 reported to contain several antigens, for example the well-known Peb antigens (Peb1A, 2, 3
431 and 4), which play roles in adhesion, invasion, and survival, and the surface antigens CjaA and
432 CjaC, which promote inflammation [62], [65-67]. The serine protease HtrA—responsible for
433 the disruption of tight and adherens junctions during invasion—was identified in the BEV
434 content of strains 81-176, 11168, and 11168H. Interestingly, vesicles also contained some
435 components of efflux pumps, like CmeA and CmeC, which have been implicated in antibiotic
436 resistance and survival [66], [67]. Finally, several studies have reported the presence of the
437 CDT subunits CdtA, CdtB, and CdtC in vesicles secreted by different strains of *C. jejuni*. In brief,
438 proteomic analyses of BEV content have confirmed that numerous virulence factors,
439 representing all steps of *C. jejuni* pathogenesis, are packed into these vesicles [52], [62].

440

Virulence factor	Type	Role	Step of pathogenesis concerned	Reference
FlaA and FlaB	Flagellins	Corkscrew motility, immune stimulating	Reaching target cells Adhesion Invasion	[65], [66], [67]
FlaC	Flagellins			[67]
FlaD	Putative flagellin			[65]
FlaE and FlgP	Flagellar hook proteins			[67]
FlgL, FlgE and FlgC				[67], [68]
FliD and FlgK	Flagellar hook proteins			[65]
CadF	Fibronectin binding protein	Adhesin	Adhesion	[62], [65], [66], [67]
FlpA		Adhesin	Adhesion	[62]
RlpA	Lipoprotein	Cell wall biogenesis	Adhesion	[67]
JlpA	Surface-exposed lipoprotein	Adhesin	Adhesion	[66]
Omp18	Outer membrane protein	Immune system stimulation	Adhesion Cell damage (via inflammation)	[67]
PorA	MOMP	Ion transport (porin) and adhesion to fibronectin	Adhesion and cell damage (porin)	[65], [67]
KpsD	Capsule polysaccharide export protein	Capsule biosynthesis	Adhesion	[65], [67]
ChuA	Outer membrane haem receptor protein	TonB-dependent heme receptor	Adhesion Invasion	[66], [67]
GroEL	Molecular chaperone	Adhesion Immune system stimulation	Adhesion Cell damage (via inflammation)	[67]
CheV	Chemoreceptor protein	Chemotaxis	Reaching target cells	[66]
CjaA, CjaC	Surface antigens	Immune system stimulation	Cell damage (via inflammation)	[65], [66], [67]
Peb1A, 2, 3	Major antigen protein	Biofilm formation, motility, host cell invasion	Adhesion Invasion Survival	[66], [67]
Peb4				[62], [67]
HtrA	Serine proteases and chaperone	Folding of adhesins Disruption of tight and adherens junctions	Adhesion Invasion	[62], [65], [66]
CmeA and CmeC	Efflux pump subunits	Resistance to broad range of antimicrobial	Survival	[66], [67]
CdtA, CdtB and CdtC	Cytolethal distending toxin subunits	DNase like protein toxin making double	Cell damage (via DNA damage)	[52], [62], [67]

		DNA break in host cells		
--	--	-------------------------	--	--

441 **Table 1. Virulence factors of *Campylobacter jejuni* found in the proteinaceous cargo of**
442 **bacterial extracellular vesicles (BEVs) by proteomic studies and the contribution of these**
443 **factors to the pathogenic process. MOMP = major outer membrane protein**

444

445 Recently, Khan *et al.* demonstrated that BEVs of *C. jejuni* with different cargos and
446 morphological attributes induced different, biologically relevant host responses [69]. They
447 reported that host cell-specific differences in BEV uptake from the extracellular milieu were
448 mediated by heterogeneity in vesicles caused by underlying differences in the membrane
449 phospholipids acquired from the source bacteria and the abundance of surface proteins.
450 Furthermore, when human and avian cells were compared as host models, the uptake of
451 different OMVs was observed to vary preferentially among different target cells. This suggests
452 that better characterization of individual BEVs may shed light on their complex roles in
453 bacterial infections.

454 With respect to BEV characterization, it is interesting to note that *C. fetus* releases BEVs
455 with a distinctive S-layer on the surface [70]. This S-layer is a bidimensional crystalline
456 structure formed by various surface-layer proteins, which mediates the evasion of the
457 immune response and is involved in cell adhesion. Moreover, the S-layer serves as a means of
458 protection from external stress for the bacterium. BEVs coated with an S-layer are probably
459 more resistant to adverse environmental conditions, which may prolong the life of the
460 released vesicles. It remains to be seen whether other *Campylobacter* species also produce
461 BEVs enveloped with an S-layer.

462

463 **4. Conclusion**

464 Despite the large amount of energy resources required, the non-lytic production of BEVs
465 throughout the life of a bacterium is evolutionarily conserved in both Gram-negative and
466 Gram-positive species. In Gram-negative bacteria, BEVs can be released from different cellular
467 locations and, due to the protection provided by the lipid bilayer, enable the transportation
468 of various molecules in their active forms. BEVs are involved in many cellular functions,
469 including mediating bacterial adaptation to various environments, facilitating intercellular
470 communication, delivering virulence factors, or transferring DNA.

471 In *C. jejuni*, BEVs are associated with the maintenance of virulence, stress response,
472 improvements in cell adherence, colonization in different hosts, and responses to signals from
473 the host gut and microbiota. The lipid bilayer protects transported molecules from host
474 proteases and immune cells and delivers molecules directly to or near their target.
475 Additionally, vesicles can play a significant role in bacterial communication by transporting
476 molecules between cells.

477 Although many studies have reported on the biogenesis and function of bacterial
478 extracellular vesicles, the formation and role of BEVs in campylobacters merit further
479 investigation. Depending on the environmental signals present, temperature, or the identity
480 of the host (avian or human cells), *C. jejuni* releases BEVs of various sizes, charges, and cargos,
481 but the reasons and mechanisms underlying these differences remain unclear. New analytical
482 methods are needed to distinguish the variety of regulatory roles these structures play during
483 pathogenesis. In particular, imaging techniques that enable dynamic monitoring are sorely
484 needed for investigations of the biogenesis and fate of BEVs. Additionally, further research is
485 required into the mechanisms by which BEV content and function adapt to the external
486 environment of the bacterium; such knowledge will help to elucidate the specific functions of
487 BEVs in pathogenesis. Based on proteomic studies, it is clear that BEVs transport a high

488 diversity of virulence factors with roles in all steps of infection, plainly demonstrating that BEV
489 secretion is a key mechanism for *C. jejuni* virulence. Identification of the factors that influence
490 the production and composition of BEVs in the gut will be key in improving our understanding
491 of both *Campylobacter* physiology and the functioning of holobionts.

492

493 **Authors contributions**

494 Authors contribute equally to this work.

495

496 **Declaration of competing interest**

497 The authors have no conflicts of interest to declare.

498

499 **Acknowledgments**

500 This work was supported by an ANR grant (Project ANR-21-CE42-0008 ELISE) and the INRAE's
501 department MICA (Project Vélib). We thank Thierry Meylheuc and Christine Longin for their
502 expertise and the MIMA2 platform for access to electron microscopy equipment (MIMA2,
503 INRAE, 2018. Microscopy and Imaging Facility for Microbes, Animals and Foods,
504 <https://doi.org/10.15454/1.5572348210007727E12>).

505

506 **References**

- 507 [1] G. V. Lopes, T. Ramires, N. R. Kleinubing, L. K. Scheik, Â. M. Fiorentini, et W. Padilha da Silva,
508 « Virulence factors of foodborne pathogen *Campylobacter jejuni* », *Microb Pathog*, vol. 161, n°
509 Pt A, p. 105265, déc. 2021, doi: 10.1016/j.micpath.2021.105265.
- 510 [2] « *Campylobacter* - Key facts », World Health Organization. Consulté le: 5 février 2024. [En ligne].
511 Disponible sur: <https://www.who.int/news-room/fact-sheets/detail/Campylobacter>
- 512 [3] Centers for Disease Control and Prevention (U.S.), « Antibiotic resistance threats in the United
513 States, 2019 », Centers for Disease Control and Prevention (U.S.), nov. 2019. doi:
514 10.15620/cdc:82532.
- 515 [4] European Food Safety Authority et European Centre for Disease Prevention and Control, « The
516 European Union One Health 2020 Zoonoses Report », *EFSA Journal*, vol. 20, n° 12, p. e06971,
517 2021, doi: 10.2903/j.efsa.2021.6971.
- 518 [5] « The European Union summary report on trends and sources of zoonoses, zoonotic agents and
519 food-borne outbreaks in 2016 », *EFSA J*, vol. 15, n° 12, p. e05077, déc. 2017, doi:
520 10.2903/j.efsa.2017.5077.
- 521 [6] M. B. Batz, S. Hoffmann, et J. G. Morris, « Ranking the disease burden of 14 pathogens in food
522 sources in the United States using attribution data from outbreak investigations and expert
523 elicitation », *J Food Prot*, vol. 75, n° 7, p. 1278-1291, juill. 2012, doi: 10.4315/0362-028X.JFP-11-
524 418.
- 525 [7] I. Hansson, M. Sandberg, I. Habib, R. Lowman, et E. O. Engvall, « Knowledge gaps in control of
526 *Campylobacter* for prevention of campylobacteriosis », *Transbound Emerg Dis*, vol. 65 Suppl 1,
527 p. 30-48, mai 2018, doi: 10.1111/tbed.12870.
- 528 [8] P. Vandamme et J. De Ley, « Proposal for a New Family, *Campylobacteraceae* », *International
529 Journal of Systematic and Evolutionary Microbiology*, vol. 41, n° 3, p. 451-455, 1991, doi:
530 10.1099/00207713-41-3-451.
- 531 [9] H. Morcrette *et al.*, « *Campylobacter jejuni* 11168H Exposed to Penicillin Forms Persister Cells
532 and Cells With Altered Redox Protein Activity », *Front Cell Infect Microbiol*, vol. 10, p. 565975,
533 2020, doi: 10.3389/fcimb.2020.565975.
- 534 [10] K. T. Young, L. M. Davis, et V. J. Dirita, « *Campylobacter jejuni*: molecular biology and
535 pathogenesis », *Nat Rev Microbiol*, vol. 5, n° 9, p. 665-679, sept. 2007, doi: 10.1038/nrmicro1718.
- 536 [11] R. E. Black, M. M. Levine, M. L. Clements, T. P. Hughes, et M. J. Blaser, « Experimental
537 *Campylobacter jejuni* infection in humans », *J Infect Dis*, vol. 157, n° 3, p. 472-479, mars 1988,
538 doi: 10.1093/infdis/157.3.472.
- 539 [12] I. Nachamkin, B. M. Allos, et T. Ho, « *Campylobacter* species and Guillain-Barré syndrome », *Clin
540 Microbiol Rev*, vol. 11, n° 3, p. 555-567, juill. 1998, doi: 10.1128/CMR.11.3.555.
- 541 [13] B. M. Allos, « *Campylobacter jejuni* Infections: update on emerging issues and trends », *Clin Infect
542 Dis*, vol. 32, n° 8, p. 1201-1206, avr. 2001, doi: 10.1086/319760.
- 543 [14] R. L. Ferrero et A. Lee, « Motility of *Campylobacter jejuni* in a viscous environment: comparison
544 with conventional rod-shaped bacteria », *J Gen Microbiol*, vol. 134, n° 1, p. 53-59, janv. 1988, doi:
545 10.1099/00221287-134-1-53.
- 546 [15] S. L. Svensson, M. Pryjma, et E. C. Gaynor, « Flagella-mediated adhesion and extracellular DNA
547 release contribute to biofilm formation and stress tolerance of *Campylobacter jejuni* », *PLoS One*,
548 vol. 9, n° 8, p. e106063, 2014, doi: 10.1371/journal.pone.0106063.
- 549 [16] C. C. Grant, M. E. Konkel, W. Cieplak, et L. S. Tompkins, « Role of flagella in adherence,
550 internalization, and translocation of *Campylobacter jejuni* in nonpolarized and polarized
551 epithelial cell cultures », *Infect Immun*, vol. 61, n° 5, p. 1764-1771, mai 1993, doi:
552 10.1128/iai.61.5.1764-1771.1993.
- 553 [17] A. Diepold et J. P. Armitage, « Type III secretion systems: the bacterial flagellum and the
554 injectisome », *Philos Trans R Soc Lond B Biol Sci*, vol. 370, n° 1679, p. 20150020, oct. 2015, doi:
555 10.1098/rstb.2015.0020.

- 556 [18] H.-Y. Yeh, K. L. Hiett, J. E. Line, et B. S. Seal, « Characterization and antigenicity of recombinant
557 Campylobacter jejuni flagellar capping protein FljD », *J Med Microbiol*, vol. 63, n° Pt 4, p. 602-609,
558 avr. 2014, doi: 10.1099/jmm.0.060095-0.
- 559 [19] V. Sourjik et N. S. Wingreen, « Responding to chemical gradients: bacterial chemotaxis », *Curr*
560 *Opin Cell Biol*, vol. 24, n° 2, p. 262-268, avr. 2012, doi: 10.1016/j.ceb.2011.11.008.
- 561 [20] K. Chandrashekhar, I. I. Kassem, et G. Rajashekara, « Campylobacter jejuni transducer like
562 proteins: Chemotaxis and beyond », *Gut Microbes*, vol. 8, n° 4, p. 323-334, juill. 2017, doi:
563 10.1080/19490976.2017.1279380.
- 564 [21] R. Yao, D. H. Burr, et P. Guerry, « CheY-mediated modulation of Campylobacter jejuni virulence »,
565 *Mol Microbiol*, vol. 23, n° 5, p. 1021-1031, mars 1997, doi: 10.1046/j.1365-2958.1997.2861650.x.
- 566 [22] S. Backert, M. Boehm, S. Wessler, et N. Tegtmeyer, « Transmigration route of Campylobacter
567 jejuni across polarized intestinal epithelial cells: paracellular, transcellular or both? », *Cell*
568 *Communication and Signaling*, vol. 11, n° 1, p. 72, sept. 2013, doi: 10.1186/1478-811X-11-72.
- 569 [23] I. Sharafutdinov, D. S. Esmaeili, A. Harrer, N. Tegtmeyer, H. Sticht, et S. Backert, « Campylobacter
570 jejuni Serine Protease HtrA Cleaves the Tight Junction Component Claudin-8 », *Front Cell Infect*
571 *Microbiol*, vol. 10, p. 590186, 2020, doi: 10.3389/fcimb.2020.590186.
- 572 [24] I. Moser, W. Schroeder, et J. Salnikow, « Campylobacter jejuni major outer membrane protein
573 and a 59-kDa protein are involved in binding to fibronectin and INT 407 cell membranes », *FEMS*
574 *Microbiol Lett*, vol. 157, n° 2, p. 233-238, déc. 1997, doi: 10.1111/j.1574-6968.1997.tb12778.x.
- 575 [25] M. E. Konkel, S. G. Garvis, S. L. Tipton, D. E. Anderson, et W. Cieplak, « Identification and
576 molecular cloning of a gene encoding a fibronectin-binding protein (CadF) from Campylobacter
577 jejuni », *Mol Microbiol*, vol. 24, n° 5, p. 953-963, juin 1997, doi: 10.1046/j.1365-
578 2958.1997.4031771.x.
- 579 [26] C. L. Larson, D. R. Samuelson, T. P. Eucker, J. L. O'Loughlin, et M. E. Konkel, « The fibronectin-
580 binding motif within FliA facilitates Campylobacter jejuni adherence to host cell and activation
581 of host cell signaling », *Emerg Microbes Infect*, vol. 2, n° 10, p. e65, oct. 2013, doi:
582 10.1038/emi.2013.65.
- 583 [27] P. K. Talukdar, N. M. Negretti, K. L. Turner, et M. E. Konkel, « Molecular Dissection of the
584 Campylobacter jejuni CadF and FliA Virulence Proteins in Binding to Host Cell Fibronectin »,
585 *Microorganisms*, vol. 8, n° 3, p. 389, mars 2020, doi: 10.3390/microorganisms8030389.
- 586 [28] K. T. Bæk, C. S. Vegge, et L. Brøndsted, « HtrA chaperone activity contributes to host cell binding
587 in Campylobacter jejuni », *Gut Pathog*, vol. 3, n° 1, p. 13, déc. 2011, doi: 10.1186/1757-4749-3-
588 13.
- 589 [29] Z. Pei *et al.*, « Mutation in the peb1A locus of Campylobacter jejuni reduces interactions with
590 epithelial cells and intestinal colonization of mice », *Infect Immun*, vol. 66, n° 3, p. 938-943, mars
591 1998, doi: 10.1128/IAI.66.3.938-943.1998.
- 592 [30] S. S. A. Ashgar *et al.*, « CapA, an Autotransporter Protein of Campylobacter jejuni, Mediates
593 Association with Human Epithelial Cells and Colonization of the Chicken Gut », *J Bacteriol*, vol.
594 189, n° 5, p. 1856-1865, mars 2007, doi: 10.1128/JB.01427-06.
- 595 [31] Y. C. Song *et al.*, « FlaC, a protein of Campylobacter jejuni TGH9011 (ATCC43431) secreted
596 through the flagellar apparatus, binds epithelial cells and influences cell invasion », *Mol*
597 *Microbiol*, vol. 53, n° 2, p. 541-553, juill. 2004, doi: 10.1111/j.1365-2958.2004.04175.x.
- 598 [32] K. M. Holden, M. Gilbert, P. J. Coloe, J. Li, et B. N. Fry, « The role of WlaRG, WlaTB and WlaTC in
599 lipooligosaccharide synthesis by Campylobacter jejuni strain 81116 », *Microbial Pathogenesis*,
600 vol. 52, n° 6, p. 344-352, juin 2012, doi: 10.1016/j.micpath.2012.03.004.
- 601 [33] D. J. Bacon *et al.*, « Involvement of a plasmid in virulence of Campylobacter jejuni 81-176 », *Infect*
602 *Immun*, vol. 68, n° 8, p. 4384-4390, août 2000, doi: 10.1128/IAI.68.8.4384-4390.2000.
- 603 [34] V. Rivera-Amill, B. J. Kim, J. Seshu, et M. E. Konkel, « Secretion of the virulence-associated
604 Campylobacter invasion antigens from Campylobacter jejuni requires a stimulatory signal », *J*
605 *Infect Dis*, vol. 183, n° 11, p. 1607-1616, juin 2001, doi: 10.1086/320704.

- 606 [35] M. E. Konkel, B. J. Kim, V. Rivera-Amill, et S. G. Garvis, « Bacterial secreted proteins are required
607 for the internalization of *Campylobacter jejuni* into cultured mammalian cells », *Molecular*
608 *Microbiology*, vol. 32, n° 4, p. 691-701, 1999, doi: 10.1046/j.1365-2958.1999.01376.x.
- 609 [36] S. Mertins, B. J. Allan, H. G. Townsend, W. Köster, et A. A. Potter, « Role of motAB in adherence
610 and internalization in polarized Caco-2 cells and in cecal colonization of *Campylobacter jejuni* »,
611 *Avian Dis*, vol. 57, n° 1, p. 116-122, mars 2013, doi: 10.1637/10235-050412-ResNote.1.
- 612 [37] X. Cao, C. H. A. van de Lest, L. Z. X. Huang, J. P. M. van Putten, et M. M. S. M. Wösten,
613 « *Campylobacter jejuni* permeabilizes the host cell membrane by short chain
614 lysophosphatidylethanolamines », *Gut Microbes*, vol. 14, n° 1, p. 2091371, 2022, doi:
615 10.1080/19490976.2022.2091371.
- 616 [38] W. M. Johnson et H. Lior, « A new heat-labile cytolethal distending toxin (CLDT) produced by
617 *Campylobacter* spp », *Microb Pathog*, vol. 4, n° 2, p. 115-126, févr. 1988, doi: 10.1016/0882-
618 4010(88)90053-8.
- 619 [39] C. L. Pickett, E. C. Pesci, D. L. Cottle, G. Russell, A. N. Erdem, et H. Zeytin, « Prevalence of cytolethal
620 distending toxin production in *Campylobacter jejuni* and relatedness of *Campylobacter* sp. cdtB
621 gene », *Infect Immun*, vol. 64, n° 6, p. 2070-2078, juin 1996, doi: 10.1128/iai.64.6.2070-
622 2078.1996.
- 623 [40] M. Lara-Tejero et J. E. Galán, « A bacterial toxin that controls cell cycle progression as a
624 deoxyribonuclease I-like protein », *Science*, vol. 290, n° 5490, p. 354-357, oct. 2000, doi:
625 10.1126/science.290.5490.354.
- 626 [41] D. C. Hassane, R. B. Lee, et C. L. Pickett, « *Campylobacter jejuni* cytolethal distending toxin
627 promotes DNA repair responses in normal human cells », *Infect Immun*, vol. 71, n° 1, p. 541-545,
628 janv. 2003, doi: 10.1128/IAI.71.1.541-545.2003.
- 629 [42] C. A. Whitehouse, P. B. Balbo, E. C. Pesci, D. L. Cottle, P. M. Mirabito, et C. L. Pickett,
630 « *Campylobacter jejuni* cytolethal distending toxin causes a G2-phase cell cycle block », *Infect*
631 *Immun*, vol. 66, n° 5, p. 1934-1940, mai 1998, doi: 10.1128/IAI.66.5.1934-1940.1998.
- 632 [43] J. Gu *et al.*, « *Campylobacter jejuni* Cytolethal Distending Toxin Induces GSDME-Dependent
633 Pyroptosis in Colonic Epithelial Cells », *Front Cell Infect Microbiol*, vol. 12, p. 853204, 2022, doi:
634 10.3389/fcimb.2022.853204.
- 635 [44] J. Lin, L. O. Michel, et Q. Zhang, « CmeABC functions as a multidrug efflux system in
636 *Campylobacter jejuni* », *Antimicrob Agents Chemother*, vol. 46, n° 7, p. 2124-2131, juill. 2002,
637 doi: 10.1128/AAC.46.7.2124-2131.2002.
- 638 [45] R. J. Reeser, R. T. Medler, S. J. Billington, B. H. Jost, et L. A. Joens, « Characterization of
639 *Campylobacter jejuni* biofilms under defined growth conditions », *Appl Environ Microbiol*, vol.
640 73, n° 6, p. 1908-1913, mars 2007, doi: 10.1128/AEM.00740-06.
- 641 [46] M. A. Monteiro *et al.*, « Capsule polysaccharide conjugate vaccine against diarrheal disease
642 caused by *Campylobacter jejuni* », *Infect Immun*, vol. 77, n° 3, p. 1128-1136, mars 2009, doi:
643 10.1128/IAI.01056-08.
- 644 [47] Z. Li, A. J. Clarke, et T. J. Beveridge, « Gram-negative bacteria produce membrane vesicles which
645 are capable of killing other bacteria », *J Bacteriol*, vol. 180, n° 20, p. 5478-5483, oct. 1998, doi:
646 10.1128/JB.180.20.5478-5483.1998.
- 647 [48] S. Gill, R. Catchpole, et P. Forterre, « Extracellular membrane vesicles in the three domains of life
648 and beyond », *FEMS Microbiol Rev*, vol. 43, n° 3, p. 273-303, mai 2019, doi:
649 10.1093/femsre/fuy042.
- 650 [49] R. A. Ñahui Palomino, C. Vanpouille, P. E. Costantini, et L. Margolis, « Microbiota-host
651 communications: Bacterial extracellular vesicles as a common language », *PLoS Pathog*, vol. 17,
652 n° 5, p. e1009508, mai 2021, doi: 10.1371/journal.ppat.1009508.
- 653 [50] A. Hendrix et O. De Wever, « Systemically circulating bacterial extracellular vesicles: origin, fate,
654 and function », *Trends Microbiol*, vol. 30, n° 3, p. 213-216, mars 2022, doi:
655 10.1016/j.tim.2021.12.012.
- 656 [51] N. J. Bitto *et al.*, « Bacterial membrane vesicles transport their DNA cargo into host cells », *Sci*
657 *Rep*, vol. 7, n° 1, p. 7072, août 2017, doi: 10.1038/s41598-017-07288-4.

- 658 [52] B. Lindmark *et al.*, « Outer membrane vesicle-mediated release of cytolethal distending toxin
659 (CDT) from *Campylobacter jejuni* », *BMC Microbiol*, vol. 9, p. 220, oct. 2009, doi: 10.1186/1471-
660 2180-9-220.
- 661 [53] M. Toyofuku, S. Schild, M. Kaparakis-Liaskos, et L. Eberl, « Composition and functions of bacterial
662 membrane vesicles », *Nat Rev Microbiol*, vol. 21, n° 7, Art. n° 7, juill. 2023, doi: 10.1038/s41579-
663 023-00875-5.
- 664 [54] C. Pérez-Cruz, L. Delgado, C. López-Iglesias, et E. Mercade, « Outer-inner membrane vesicles
665 naturally secreted by gram-negative pathogenic bacteria », *PLoS One*, vol. 10, n° 1, p. e0116896,
666 2015, doi: 10.1371/journal.pone.0116896.
- 667 [55] A. K. Baidya, S. Bhattacharya, G. P. Dubey, G. Mamou, et S. Ben-Yehuda, « Bacterial nanotubes:
668 a conduit for intercellular molecular trade », *Curr Opin Microbiol*, vol. 42, p. 1-6, avr. 2018, doi:
669 10.1016/j.mib.2017.08.006.
- 670 [56] L. Mashburn-Warren *et al.*, « Interaction of quorum signals with outer membrane lipids: insights
671 into prokaryotic membrane vesicle formation », *Mol Microbiol*, vol. 69, n° 2, p. 491-502, juill.
672 2008, doi: 10.1111/j.1365-2958.2008.06302.x.
- 673 [57] W. Elhenawy, M. Bording-Jorgensen, E. Valguarnera, M. F. Haurat, E. Wine, et M. F. Feldman,
674 « LPS Remodeling Triggers Formation of Outer Membrane Vesicles in *Salmonella* », *mBio*, vol. 7,
675 n° 4, p. e00940-16, juill. 2016, doi: 10.1128/mBio.00940-16.
- 676 [58] C. A. Brennan *et al.*, « A model symbiosis reveals a role for sheathed-flagellum rotation in the
677 release of immunogenic lipopolysaccharide », *Elife*, vol. 3, p. e01579, mars 2014, doi:
678 10.7554/eLife.01579.
- 679 [59] S. Roier *et al.*, « A novel mechanism for the biogenesis of outer membrane vesicles in Gram-
680 negative bacteria », *Nat Commun*, vol. 7, p. 10515, janv. 2016, doi: 10.1038/ncomms10515.
- 681 [60] C. Davies *et al.*, « Sodium Taurocholate Stimulates *Campylobacter jejuni* Outer Membrane
682 Vesicle Production via Down-Regulation of the Maintenance of Lipid Asymmetry Pathway »,
683 *Front Cell Infect Microbiol*, vol. 9, p. 177, 2019, doi: 10.3389/fcimb.2019.00177.
- 684 [61] A. D. Gabbert *et al.*, « The Missing Pieces: The Role of Secretion Systems in *Campylobacter jejuni*
685 Virulence », *Biomolecules*, vol. 13, n° 1, p. 135, janv. 2023, doi: 10.3390/biom13010135.
- 686 [62] A. Elmi *et al.*, « *Campylobacter jejuni* outer membrane vesicles play an important role in bacterial
687 interactions with human intestinal epithelial cells », *Infect Immun*, vol. 80, n° 12, p. 4089-4098,
688 déc. 2012, doi: 10.1128/IAI.00161-12.
- 689 [63] R. N. Jinadasa, S. E. Bloom, R. S. Weiss, et G. E. Duhamel, « Cytolethal distending toxin: a
690 conserved bacterial genotoxin that blocks cell cycle progression, leading to apoptosis of a broad
691 range of mammalian cell lineages », *Microbiology (Reading)*, vol. 157, n° Pt 7, p. 1851-1875, juill.
692 2011, doi: 10.1099/mic.0.049536-0.
- 693 [64] A. Sałamaszyńska-Guz, P. K. Rasmussen, M. Murawska, et S. Douthwaite, « *Campylobacter jejuni*
694 Virulence Factors Identified by Modulating Their Synthesis on Ribosomes With Altered rRNA
695 Methylation », *Front Cell Infect Microbiol*, vol. 11, p. 803730, 2021, doi:
696 10.3389/fcimb.2021.803730.
- 697 [65] K.-S. Jang, M. J. Sweredoski, R. L. J. Graham, S. Hess, et W. M. Clemons, « Comprehensive
698 proteomic profiling of outer membrane vesicles from *Campylobacter jejuni* », *J Proteomics*, vol.
699 98, p. 90-98, févr. 2014, doi: 10.1016/j.jprot.2013.12.014.
- 700 [66] N. Taheri, A. K. M. F. Mahmud, L. Sandblad, M. Fällman, S. N. Wai, et A. Fahlgren,
701 « *Campylobacter jejuni* bile exposure influences outer membrane vesicles protein content and
702 bacterial interaction with epithelial cells », *Sci Rep*, vol. 8, n° 1, p. 16996, nov. 2018, doi:
703 10.1038/s41598-018-35409-0.
- 704 [67] N. Taheri, M. Fällman, S. N. Wai, et A. Fahlgren, « Accumulation of virulence-associated proteins
705 in *Campylobacter jejuni* Outer Membrane Vesicles at human body temperature », *J Proteomics*,
706 vol. 195, p. 33-40, mars 2019, doi: 10.1016/j.jprot.2019.01.005.
- 707 [68] R. Godlewska, J. Klim, J. Dębski, A. Wyszowska, et A. Łasica, « Influence of Environmental and
708 Genetic Factors on Proteomic Profiling of Outer Membrane Vesicles from *Campylobacter*
709 *jejuni* », *Pol J Microbiol*, vol. 68, n° 2, p. 255-261, 2019, doi: 10.33073/pjm-2019-027.

710 [69] A. Khan, A. Sardar, P. K. Tarafdar, et A. I. Mallick, « Heterogeneity and Compositional Diversities
711 of *Campylobacter jejuni* Outer Membrane Vesicles (OMVs) Drive Multiple Cellular Uptake
712 Processes », *ACS Infect Dis*, vol. 9, n° 11, p. 2325-2339, nov. 2023, doi:
713 10.1021/acsinfecdis.3c00422.

714 [70] P. Farace *et al.*, « *Campylobacter fetus* releases S-layered and immunoreactive outer membrane
715 vesicles », *Rev Argent Microbiol*, vol. 54, n° 2, p. 74-80, 2022, doi: 10.1016/j.ram.2021.06.001.

716

717